Context: The United States government has announced a 100% tariff on branded and patented pharmaceutical products, effective October 1, 2025. The measure exempts companies that are building or expanding manufacturing plants in the U.S., signaling Washington’s push for domestic production. While the move is aimed at reducing dependency on foreign manufacturers, it has significant implications for India, one of the largest suppliers of medicines to the U.S.
Immediate Impact on India
India’s pharmaceutical sector is heavily export-oriented, with the U.S. accounting for nearly 35% of total exports. However, the tariff’s immediate disruption is limited, because:
- Generics Safety Net: Around 85–90% of Indian pharma exports to the U.S. are generic medicines, which are excluded from the tariff. This ensures that the core of India’s export base remains secure.
- Branded Exposure: A smaller share of exports involves branded or patented drugs, mainly through companies like Sun Pharma, Dr. Reddy’s, and Cipla, which operate via subsidiaries or contract manufacturing in the U.S. These firms may face higher costs and shrinking profit margins.
- Stock Market Reaction: Following the announcement, Indian pharma stocks saw an immediate decline, reflecting investor concerns over future risks and market uncertainty.
Broader Trade Context
The decision must be seen within the larger framework of U.S. trade policy:
- The U.S. also imposed 50% tariffs on kitchen cabinets, bathroom vanities, and related products, marking a shift from country-specific tariffs (e.g., targeting China earlier) to product-specific tariffs.
- This aligns with the “tariff weaponisation” approach previously applied to furniture, trucks, and automobiles, underlining Washington’s strategic use of tariffs to promote domestic industries.
- For India, the move is a reminder to diversify export markets—for example, expanding outreach to the EU, Africa, and Latin America—to reduce reliance on the U.S. and safeguard against unpredictable policy swings.
India’s Pharmaceutical Sector
India is widely regarded as the “pharmacy of the world”, with impressive global credentials:
- Global Standing: India ranks 3rd worldwide in production by volume and 14th by value, with a 2025 industry size estimated at $66 billion.
- Generics Leader: India supplies 20% of global generic medicines and over 40% of generics consumed in the U.S., highlighting its critical role in affordable healthcare.
- Vaccine Contributor: Nearly 55–60% of UNICEF’s vaccines are sourced from Indian manufacturers.
- Government Support: Policies like the Production Linked Incentive (PLI) Scheme and the Promotion of Research and Innovation in Pharma-MedTech (PRIP) are driving R&D, affordability, and export competitiveness.
Strategic Implication
While the current tariff primarily spares Indian generics, the measure signals a potential shift in U.S. trade priorities. If expanded, tariffs on generics could significantly affect India’s export revenues, public health supply chains, and employment in the pharma sector.
India must:
- Diversify export destinations to reduce vulnerability.
- Strengthen domestic demand for high-value pharmaceuticals.
- Accelerate innovation and R&D, particularly in biologics and patented medicines, to maintain global competitiveness.
Conclusion
The 100% U.S. tariff on branded and patented drugs is not a major shock for India’s pharmaceutical industry in the short term, given its generic-heavy export profile. However, it signals the risks of overdependence on a single market. For India, the policy shift is both a warning and an opportunity—to diversify, innovate, and consolidate its position as the world’s reliable and affordable medicine hub.
